A New Frontier in the Fight Against Cancer (That Is, for Those Who Can Afford It)
The Food and Drug Administration (FDA) made history this fall with its approval of Novartis’s Kymirah and Gilead’s Yescarta—the first gene therapies to ever be approved in the United States. [1,2] Both treatments belong to a new class of cancer therapeutics called CAR T-cell treatments, which use pa...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia University Libraries
2018-01-01
|
| Series: | Voices in Bioethics |
| Subjects: | |
| Online Access: | https://journals.library.columbia.edu/index.php/bioethics/article/view/6024 |